Soluble CD26/CD30 levels in visceral leishmaniasis: Markers of disease activity

Clinical and Experimental Immunology

Volumn 145, Issue 1, 2006, Pages 44-47

  Ajdary, S ^a   Riazi Rad, F ^a   Jafari Shakib, R ^b   Mohebbali, M ^c  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

scd26; scd30; Visceral leishmaniasis

Indexed keywords

CD30 ANTIGEN; DIPEPTIDYL PEPTIDASE IV;

ARTICLE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; LEISHMANIA DONOVANI; MALE; PRIORITY JOURNAL; SERUM; SOLUBILITY; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIGENS, CD26; ANTIGENS, CD30; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFANT; IRAN; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; MALE; STATISTICS, NONPARAMETRIC; TH1 CELLS; TH2 CELLS;

EID: 33745126260     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2006.03105.x     Document Type: Article

References (30)

1. Edrissian GH Hafezi A Afshar A et al. An endemic focus of visceral leishmaniasis in Meshkin-Shahr, East Azerbaijan province, North-West part of Iran and IFA serological survey of the disease in the area. Bull Soc Pathol Exot 1988 81 : 238 48.
2. Davies CR Mazloumi Gavgani AS. Age acquired immunity and the risk of visceral leishmaniasis: a prospective study in Iran. Parasitology 1999 119 : 247 57.
3. Navin TR Sierra M Custodio R Steuerer F Porter CH Reubush TK. Epidemiological study of visceral leishmaniasis in Honduras, 1975-83. Am J Trop Med Hyg 1985 34 : 1069 75.
4. Badaro R Jones TC Carvalho EM et al. New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis 1986 154 : 1003 11.
5. Carvalho EM Barral A Pedral-Sampaio D et al. Immunologic markers of clinical evolution in children recently infected with Leishmania donovani Chagasi. J Infect Dis 1992 165 : 535 40.
6. Mary CH Auriault V Faugere B Dessien A. Control of leishmania infantum infection is associated with CD8 and gamma-interferon and IL-5-producing CD4 antigen-specific T cells. Infect Immun 1999 67 : 55559 66.
7. Kenney RT Sacks DL Gam AA Murray HW Sundar SH. Splenic cytokine response in Indian kala-azar before and after treatment. J Infect Dis 1998 177 : 815 9.
8. Carvalho EM Bacellar O Brownell C Regis T Coffman RL Reed SG. Restoration of IFN-γ production and lymphocyte proliferation in visceral leishmaniasis. J Immunol 1994 152 : 5949 56.
9. Cillari E Vitale G Arcoleo F et al. In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. Cytokine 1995 7 : 740 5.
10. Zwingenberger K Harms G Pedrosa C Omena S Sandkamp B Neifer S. Determinants of the immune response in visceral leishmaniasis: evidence of predominance of endogenous interleukin-4 over interferon-γ production. Clin Immunol Immunopath 1990 57 : 242 9.
11. Ghalib HW Pavezam MR Skeiky YM et al. Interleukin-10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 1993 92 : 324 9.
12. Holaday BJ Pompeu MM Jeronimo S et al. Potential role for interleukin-10 in the immunosuppression associated with kala azar. J Clin Invest 1993 92 : 2626 32.
13. Gasim SEI Hassan AM Khalil EA et al. High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. Clin Exp Immunol 1998 111 : 64 9.
14. Sacks D Anderson CH. Re-examination of the immunosuppressive mechanisms mediating non-cure of leishmania infection in mice. Immunol Rev 2004 201 : 225 38.
15. Del Prete G De Carli M Almerigogna F et al. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokine. FASEB J 1995 9 : 81 6.
16. Scheel-Toelner D Richter E Toelner KM et al. CD26 expression in leprosy and other granulomatous diseases correlation with the production of IFN-γ. Lab Invest 1995 73 : 685 90.
17. Willheim M Ebner C Baier K et al. Cell surface characterization of T lymphocyte and allergen-specific T cell clones: correlation of CD26 expression with Th1 subsets. J Allergy Clin Immunol 1997 100 : 348 55.
18. Salgado FJ Vela E Martin M Franco R Nogueira M Cordero OJ. Mechanisms of CD26/dipeptidyl peptidase IV cytokine-dependent regulation on human activated lymphocytes. Cytokine 2000 12 : 1136 41.
19. Katoh N Hirano S Suehiro M et al. Soluble CD30 is more relevant to disease activity of atopic dermatitis than soluble CD26. Clin Exp Immunol 2000 121 : 187 92.
20. Foschi FG Gramenzi A Castelli E et al. Soluble CD30 serum level in HCV-positive chronic active hepatitis: a surrogate marker of disease activity? Cytokine 2000 12 : 815 8.
21. Fattovich G Vinante F Giustina G et al. Serum level CD30 in chronic hepatitis B virus infection. Clin Exp Immunol 1996 103 : 105 10.
22. Kobayashi H Hosono O Mimori T et al. Reduction of serum soluble CD26/dipeptidyl IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus. J Rheumatol 2002 29 : 1858 66.
23. Belkaid y Piccirillo CA Mendez S Shevach EM Sacks DL. CD4 CD25 regulatory T cells control Leishmania major persistence and immunity. Nature 2002 420 : 502 7.
24. Belkaid Y Hoffmann KF Mendez S et al. The role of IL-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 2001 194 : 1497 506.
25. Kane MM Mosser DM. The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 2001 166 : 1141 7.
26. Romagnani S. Th1 and Th2 in human disease. Clin Immunol Immunopathol 1996 80 : 225 35.
27. De Pita O Frezzolini A Cianchini G Ruffelli M Teofoli P Pudda P. Th-helper 2 involvement in the pathogenesis of bullous pemphigoid: role of soluble CD30 (Scd30). Arch Dermatol Res 1997 280 : 667 70.
28. Frezzolini A Cianchini G Ruffelli M Cadoni S Pudda P De Pita O. Interleukin-16 expression and release in bullous pemphigoid. Clin Exp Immunol 2004 137 : 595 600.
29. Liao Y Po-Yen CH Lin CH Fu L Chiu CH Chi CH. Soluble CD26/30 levels before and after treatment with IFN-α and ribavirin combination therapy in a pediatric hepatitis C patient. J Microbiol Immunol Infect 2004 37 : 67 70.
30. Schonermarck U Csernok E Trabandt A Hansen H Gross WL. Circulating cytokines and soluble CD23, CD26 and CD30 in ANCA-associated vasculitides. Clin Exp Rheumatol 2000 18 : 457 63.